I understand where you’re coming from about the cycles we’ve seen here, and it’s true that the OTC is full of patterns like that. But at the same time, not every chapter is destined to be a repeat of the last. The real question now isn’t whether we’ll see another 2021-type spike—it’s whether Dalton finally puts the kind of foundation in place that separates hype from a lasting move.

Uplisting will never happen off message board chatter, but off contracts, revenue, and real partnerships. That’s the line in the sand. If one of the big-name connections being hinted at does come forward in a verifiable way, then we’re not talking about “another hype run” at all—it’s a different league.

I’ve always tried to stay cautious but hopeful, and that hasn’t changed. The past doesn’t erase the possibility of a very different outcome if substance finally shows up.